ArticleCancer discovery2021
Bacterial-Driven Inflammation and Mutant
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
9.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- A comprehensive overview of the molecular features and therapeutic targets in BRAFClinical and translational medicine · 2024Pooled it
- Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.Frontiers in immunology · 2023Pooled it
- A systemic review of the role of enterotoxic Bacteroides fragilis in colorectal cancer.Neoplasia (New York, N.Y.) · 2022Pooled it
- Colorectal cancer landscape from gut microbiota: Insights into mutations, epigenetic dysregulation, and immune microenvironment alterations.Virulence · 2026Review
- Enterotoxigenic Bacteroides fragilis Induces Host Genotype-Specific Colonic Epithelial and Immune Responses in Mice.The Journal of infectious diseases · 2026Article
- Microbiome-Shaped Metastatic Niches in Colorectal Cancer: Organ-Specific Patterns, Immune-Metabolic Mechanisms, and Therapeutic Translation.Microorganisms · 2026Review
- Harnessing the microbiome for cancer therapy.Nature reviews. Microbiology · 2026Review
- Microbiota-host interaction in colorectal cancer: emerging computational technology, multi-omics integration, and mechanisms.Cancer biology & medicine · 2026Review
- Evaluating the anti-gut dysbiotic potential of bioactive primary metabolites derivatives fromFrontiers in nutrition · 2026Article
- Colorectal cancer-derived extracellular vesicles: at the crossroads of the tumor microenvironment and gut microbiota.Frontiers in immunology · 2026Review
- Deciphering intratumoral microbiota in digestive system tumors: mechanisms and emerging therapeutic strategies.Frontiers in cellular and infection microbiology · 2026Review
- Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic.Frontiers in pharmacology · 2026Review
- Fosl1 is a transcriptional effector ofiScience · 2025Article
- Mast cells interact directly with colorectal cancer cells to promote epithelial-to-mesenchymal transition.Oncogene · 2025Article
- Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer.Nature reviews. Cancer · 2025Review
- Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations.NPJ biofilms and microbiomes · 2025Review
- Targeting the Tumor Microbiota in Cancer Therapy Basing on Nanomaterials.Exploration (Beijing, China) · 2025Review
- Modeling ETBF-Mediated Colorectal Tumorigenesis Using AOM/DSS in Wild-Type Mice.International journal of molecular sciences · 2025Article
- Intestinal dysbiosis and colorectal cancer.Chinese medical journal · 2025Review
- Gut microbiota in cancer initiation, development and therapy.Science China. Life sciences · 2025Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 1 country.
Christina E DeStefano ShieldsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4714-3423
James R WhiteResphera Biosciences, Baltimore, Maryland.
Liam ChungDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Alyssa WenzelDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jessica L HicksDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ada J TamBloomberg-Kimmel Institute for Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland.
June L ChanDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Christine M DejeaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Hongni FanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
John MichelDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4456-2630
Ashley R MaiuriMedical Sciences, Cell, Molecular and Cancer Biology Program, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Bloomington, Indiana.
Shruthi SriramkumarMedical Sciences, Cell, Molecular and Cancer Biology Program, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Bloomington, Indiana.ORCID 0000-0003-1308-2546
Ram PodichetiCenter for Genomics and Bioinformatics, Indiana University, Bloomington, Indiana.
Douglas B RuschCenter for Genomics and Bioinformatics, Indiana University, Bloomington, Indiana.
Hao WangDivision of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Angelo M De MarzoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4847-5307
Sepideh BesharatiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3200-1895
Robert A AndersDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Stephen B BaylinDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Heather M O'Hagan *Medical Sciences, Cell, Molecular and Cancer Biology Program, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Bloomington, Indiana. hmohagan@indiana.edu fhousse1@jhmi.edu csears@jhmi.edu.ORCID 0000-0001-9750-5088
Franck Housseau *Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. hmohagan@indiana.edu fhousse1@jhmi.edu csears@jhmi.edu.
Cynthia L Sears *Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. hmohagan@indiana.edu fhousse1@jhmi.edu csears@jhmi.edu.ORCID 0000-0003-4059-1661
Johns Hopkins University · USBloomberg (United States) · USIndiana University Bloomington · USJoint Center for Structural Genomics · USMt. Washington Pediatric Hospital · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6MMedical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4MDNA Methyltrasferase Gene Expression in Colon CancerR01ES011858 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI BAYLIN, STEPHEN B., EASWARAN, HARIHARAN · 2002 to 2023
$11.5MCorrelates of antitumor immunity in colorectal cancers and anti PD1 therapyR01CA203891 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOUSSEAU, FRANCK · 2016 to 2020
$1.9MToxin-Associated Oxidative DNA Damage Initiates Tumor-Specific Epigenetic ChangesR01ES023183 · NIEHS · INDIANA UNIVERSITY INDIANAPOLIS · PI O'HAGAN, HEATHER M · 2013 to 2016
$1.6MCancer Research UK 27140Cancer Research UK C10674/A27140NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA203891NIEHS NIH HHS R01 ES011858NIEHS NIH HHS R01 ES023183NIGMS NIH HHS T32 GM136577
Abstract
Colorectal cancer is multifaceted, with subtypes defined by genetic, histologic, and immunologic features that are potentially influenced by inflammation, mutagens, and/or microbiota. Colorectal cancers with activating mutations in
Indexed as
AnimalsBacteroides fragilisCarcinogenesisCell Transformation, NeoplasticColorectal NeoplasmsDisease Models, AnimalMiceMice, Inbred C57BLMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.